Key result
Catheter-based renal denervation is a promising treatment for resistant hypertension, but unresolved issues must be addressed before it can be embraced as mainstream therapy.
This review summarizes contemporary evidence, devices, and future directions for catheter-based renal denervation in resistant hypertension and other conditions.
Answers are grounded in this paper and cite their sources.
Cautions against routine renal denervation use; leaves open its mainstream role pending resolution of outstanding issues.
Hypertension has a considerable worldwide burden and is a major risk factor for cardiovascular disease. Despite the use of lifestyle measures and medical therapy, a large proportion of patients remain treatment ‘resistant’ and fail to have adequate control of blood pressure. This may adversely affect both future cardiovascular events and mortality. Catheter-based renal denervation is a promising contemporary evolution of a historical treatment for hypertension and aims to achieve a reduction in renal sympathetic activation. This has been shown previously to be important in both resistant hypertension and in other disease states including heart failure. This review will focus on contemporary evidence supporting the utility of renal denervation, review current and emerging devices, consider potential future treatment indications, and discuss unresolved issues that need to be addressed before renal denervation can be embraced as mainstream therapy.
No takes yet. Share an insight, caveat, or question.
Sathananthan et al. (2014) conducted a review in Hypertension. Catheter-based renal denervation was evaluated. Catheter-based renal denervation is a promising treatment for resistant hypertension, but unresolved issues must be addressed before it can be embraced as mainstream therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: